Accretion Nutraveda Ltd vs Alivus Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 14, 2026

Key Highlights

The Latest Trading Price of Accretion Nutraveda Ltd is ₹ 261 as of 14 May 15:30 . The P/E Ratio of Accretion Nutraveda Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 27.2 on March 2025 . This represents a CAGR of 19.36% over 4 years The Market Cap of Accretion Nutraveda Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 13229 crore on March 2025 . This represents a CAGR of 23.84% over 4 years The revenue of Accretion Nutraveda Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Alivus Life Sciences Ltd for the Dec '25 is ₹ 686.82 crore as compare to the Sep '25 revenue of ₹ 602.7 crore. This represent the growth of 13.96% The ebitda of Accretion Nutraveda Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Alivus Life Sciences Ltd for the Dec '25 is ₹ 219.54 crore as compare to the Sep '25 ebitda of ₹ 193.89 crore. This represent the growth of 13.23% The net profit of Accretion Nutraveda Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Alivus Life Sciences Ltd changed from ₹ 111.48 crore to ₹ 150.26 crore over 7 quarters. This represents a CAGR of 18.60% The Dividend Payout of Accretion Nutraveda Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 years .

About Accretion Nutraveda Ltd

Accretion Nutraveda Limited was initially incorporated as a Private Limited Company on March 16, 2021 and has subsequently, converted the status into a Public Limited Company vide Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre w.e.f.
May 2, 2025. The Company, established at Ahmedabad, is a healthcare-focused Contract Development and Manufacturing Organization (CDMO), offering specialized services to a diverse range of clients across the various industries.
It specialize in ayurvedic and nutraceutical products including Tablets, Capsules, Oral Liquids, Oral Powders, External Preparation and Oils.
Apart from these, it offer a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. The products include Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

FAQs for the comparison of Accretion Nutraveda Ltd and Alivus Life Sciences Ltd

Which company has a larger market capitalization, Accretion Nutraveda Ltd or Alivus Life Sciences Ltd?

Market cap of Accretion Nutraveda Ltd is 188 Cr while Market cap of Alivus Life Sciences Ltd is 13,042 Cr

What are the key factors driving the stock performance of Accretion Nutraveda Ltd and Alivus Life Sciences Ltd?

The stock performance of Accretion Nutraveda Ltd and Alivus Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Nutraveda Ltd and Alivus Life Sciences Ltd?

As of May 14, 2026, the Accretion Nutraveda Ltd stock price is INR ₹261.0. On the other hand, Alivus Life Sciences Ltd stock price is INR ₹1062.65.

How do dividend payouts of Accretion Nutraveda Ltd and Alivus Life Sciences Ltd compare?

To compare the dividend payouts of Accretion Nutraveda Ltd and Alivus Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.